Subscribe
Logo small
Search
banner

Poland's historic advance in terms of access to innovative drugs

MedExpress Team

Katarzyna Wróblewska

Published April 28, 2023 11:36

Poland's historic advance in terms of access to innovative drugs - Header image
April 28 this year. The European Federation of Pharmaceutical Industries and Associations (EFPIA) released the results of its annual W.A.I.T. survey. Poland recorded the largest W.A.I.T. in the nearly 20-year history of the survey in terms of accessibility to innovative drugs.

W.A.I.T. (Waiting to Access Innovative Therapies) is an annual study by the European Federation of Pharmaceutical Industries and Associations that analyzes waiting times for patients to access innovative therapies.

The latest list, just published, compared access to 168 innovative therapies in 37 European countries. Poland recorded the biggest promotion in the nearly 20-year history of W.A.I.T. - moving from 25th to 21st place in terms of drug availability. 35% of the innovative therapies analyzed are available in our country. This is a significant change from last year's results, according to which only 26% of therapies could be used for Polish patients. Germany remains the leader, with 147 available therapies. The other positions on the podium are occupied by Italy and Austria. In the overall ranking, Poland is ahead of, among others, two Visegrad Group countries - Hungary and Slovakia - and the Baltic countries - Lithuania, Latvia and Estonia. However, the rate of full accessibility shows areas for further improvement, with as many as 78% of the 59 therapies reimbursed in Polan...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.

Read also